The Global Drug Market for Dermatological Conditions Associated with Ageing and Lifestyle is Estimated at US$1.8 Billion in 2005.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c28592) has announced the addition of The Global Image Dermatology Drug Market, 2005-2012: High-Growth Opportunities in Aesthetic Medicine to their offering. Examines the global market for aesthetic dermatologicals and specialty physician-dispensed drugs to treat conditions associated with deficits in physical image and form. Drugs such as botulinum toxins, retinoids Retinoids A derivative of synthetic Vitamin A. Mentioned in: Ichthyosis retinoids (reˑ·t , acid peels, 5-alpha reductase reductase /re·duc·tase/ (-tas) a term used in the names of some of the oxidoreductases, usually specifically those catalyzing reactions important solely for reduction of a metabolite. and lipase lipase (lī`pās), any enzyme capable of degrading lipid molecules. The bulk of dietary lipids are a class called triacylglycerols and are attacked by lipases to yield simple fatty acids and glycerol, molecules which can permeate the membranes inhibitors associated with cutaneous cutaneous /cu·ta·ne·ous/ (ku-ta´ne-us) pertaining to the skin. cu·ta·ne·ous adj. Of, relating to, or affecting the skin. Cutaneous Pertaining to the skin. ageing, photodamage, pigmentation pigmentation, name for the coloring matter found in certain plant and animal cells and for the color produced thereby. Pigmentation occurs in nearly all living organisms. defects, alopecia alopecia (ăl'əpē`shēə): see baldness. , and the lipodermal disorders of obesity and gynoid lipodystrophy are critically discussed to provide a detailed analysis of the high-growth market sector estimated at US$1.8 billion in 2005 and forecast to increase by 114% to US$3.9 billion by 2012. The report includes insights for product extension and optimization, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. Therapy area forecasting and illustrative market data and analysis is also presented to gain insight into top-performing products and therapy areas. Objectives of the Report Briefing The objectives of this report are to provide a detailed analysis of the global image dermatology drug market. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. The report briefing also aims to expand knowledge of the therapeutic areas and to highlight the role of antiageing medicines and lifestyle drugs in an increasingly ageing world population. It is hoped that the reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities. Image dermatology is a high-growth market opportunity based on the increasing numbers of people turning to medical and surgical intervention to combat signs of cutaneous ageing and to correct perceived deficits in physical form. Demand for therapeutic dermatologicals to treat conditions such as alopecia, cutaneous ageing, photodamage, skin pigmentation, and the lipodermal disorders of obesity and gynoid lipodystrophy (cellulite cel·lu·lite n. A fatty deposit causing a dimpled or uneven appearance, as around the thighs. Cellulite Cellulite is dimply skin caused by uneven fat deposits beneath the surface. ) will be driven by factors such as increasing worldwide ageing populations; unrelenting media fixation on physical improvement and restorative antiageing treatments; and innovation in the pharmaceutical industry to bring to market highly sophisticated efficacious drug treatments that serve to close the gap between medical and cosmetic interventions. The global drug market for dermatological conditions associated with ageing and lifestyle is estimated at US$1.8 billion in 2005 and is forecast to increase by 114% to US$3.9 billion by 2012. In this report, The Global Image Dermatology Drug Market, 2005-2012: High-Growth Opportunities in Aesthetic Medicine, the reader will be introduced to a specialty pharmaceutical therapy area that is poised for significant expansion based on new pharmacotherapies to address cutaneous ageing, pigmentation disorders, obesity and gynoid lipodystrophy. The report provides a detailed analysis of the sector to include insights for product extension and optimization, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. Each therapy area segment concludes with a summary of the key issues that are considered to affect growth and sustainability. An overview of R&D programs within the field is also highlighted showing products from preclinical to premarket authorization phases of development. Promising agents are discussed in relation to development status and commercial prospects. Therapy area forecasting and illustrative market data and analysis are also presented to provide an insight into top-performing products and sales estimates to 2012. Therapy forecasting to 2020 is also detailed to enable the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modeling. Companies Mentioned: Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals and health care company. It has over 65,000 employees and operates in 130 countries. The corporate headquarters are in Abbott Park, Illinois, a neighborhood of North Chicago, Illinois. Serono Alizyme Shionogi Allergan Solvay Pharmaceuticals Amgen Stiefel Laboratories Amylin Pharmaceuticals Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. Currently, Amylin produces two drugs, Symlin (pramlintide acetate) and Byetta (exenatide). Amylin also is working on producing a drug based on Leptin. Targacept Arena Pharmaceuticals Valeant Pharmaceuticals Astellas Pharma Astellas Pharma Inc. (アステラス製薬株式会社 Vernalis Barrier Therapeutics Wyeth Bertek Pharmaceuticals Bioaccelerate Biotecon Therapeutics Biovitrium Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Chiron Curis Dainippon Sumitomo Pharmaceuticals Eisai Elan Enhance Biotech Epitan Fasgen Galderma Genaera Glades Glades may refer to:
Glaxosmithkline Genaderm Inamed Intercytex Ipsen Isolagen Karo KARO Kane Amateur Radio Operators (Kane, PA) Bio Ligand Mentor Merck Merz Pharma Metabolic Pharmaceuticals Millennium Nastech Neurogen Obagi Medical Products Ortho-Mcneil Pharmaceuticals Pfizer Pherin Pharmaceuticals Predix Pharma Phytopharm Roche Sanofi-Aventis Sapphiretherapeutics For more information visit http://www.researchandmarkets.com/reports/c28592 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion